In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics
Anthracycline antibiotics (ANT) are among the most widely used anticancer drugs. Unfortunately, their use is limited due to the development of drug resistance and cardiotoxicity. ANT metabolism, performed mainly by two enzymes—aldo-keto reductase 1C3 (AKR1C3) and carbonyl reductase 1 (CBR1)—is one o...
Main Authors: | Marek Jamrozik, Kamil Piska, Adam Bucki, Paulina Koczurkiewicz-Adamczyk, Michał Sapa, Benedykt Władyka, Elżbieta Pękala, Marcin Kołaczkowski |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/28/9/3767 |
Similar Items
-
Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors
by: Sonu S. Varghese, et al.
Published: (2021-10-01) -
Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
by: Alexandros Briasoulis, et al.
Published: (2022-02-01) -
RISK FACTORS AND INCIDENCE OF MYOCARDIAL DAMAGE IN PATIENTS WITH HEMOBLASTOSIS RECEIVING ANTHRACYCLIN ANTIBIOTICS
by: N. T. Vatutin, et al.
Published: (2017-10-01) -
Semi-rational engineering an aldo–keto reductase for stereocomplementary reduction of α-keto amide compounds
by: Ruixuan Bai, et al.
Published: (2023-10-01) -
The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy
by: Jaroslaw Szponar, et al.
Published: (2023-06-01)